Kaufman Rossin Wealth’s Biogen BIIB Stock Holding History

Kaufman Rossin Wealth’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,690	Closed	-$231K	–	148
2025 Q1	$231K	Buy	+1,690	New	+$242K	0.17%	122

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kaufman Rossin Wealth's BIIB Position: Q2 2025 in Review

Kaufman Rossin Wealth sold out of Biogen (BIIB) in Q2 2025, closing a stake of 1,690 shares — an estimated $231K sold.

Kaufman Rossin Wealth first reported a position in BIIB in Q1 2025 and held it in 1 quarter. The position peaked at $231K in Q1 2025. 866 funds tracked by Wall St. Rank hold BIIB as of Q2 2025.

Kaufman Rossin Wealth reported no remaining Biogen position as of Q2 2025 after selling out during the quarter.
Kaufman Rossin Wealth sold 1,690 Biogen shares in Q2 2025, an estimated $231K.
Kaufman Rossin Wealth first reported a position in Biogen in Q1 2025 and held it in 1 quarter.
Kaufman Rossin Wealth's Biogen position peaked at $231K in Q1 2025.
866 funds tracked by Wall St. Rank held Biogen as of Q2 2025.

Based on Kaufman Rossin Wealth's 13F filing for Q2 2025, filed 11 Jul 2025.